Evidence map›Paper›PMID 36241994›Full record

ArticleBMC cancer2022

The combination of serum oligosaccharide chain (G-test), alpha-fetoprotein, and aspartate aminotransferase to alanine aminotransferase ratio provides the optimal diagnostic value for early detection of hepatocellular carcinoma.

Wentao Zhu, Pei Shi, An Liang, Ying Zhu, Jiwei Fu, Songsong Yuan, Xiaoping Wu

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. [Expert recommendations on screening, testing and management for hepatitis B virus infection in adults].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wentao ZhuDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Pei ShiDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China.
An LiangDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Ying ZhuDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Jiwei FuDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Songsong YuanDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China. Yuansong5255@163.com.
Xiaoping WuDepartment of Infectious Diseases, the First Affiliated Hospital of Nanchang University, Nanchang, China. wuxiaoping2823@aliyun.com.
Nanchang University · CNFirst Affiliated Hospital of Nanchang University · CN

Funding

Health Commission of Jiangxi Province 20202097Natural Science Foundation of Jiangxi Province 20212ACB206010
6 · The paper itself

Abstract

backgroundThe purpose of this study was to compare the diagnostic value of serum oligosaccharide chain (G-test), alpha-fetoprotein (AFP) and aspartic aminotransferase to alanine aminotransferase ratios (AAR), both alone and in combination, for predicting hepatocellular carcinoma (HCC) onset.

methodsBetween Januarys 2020-2022, 152 subjects admitted to the First Affiliated Hospital of Nanchang University was enrolled in this study, of which 77 had HCC, 18 chronic hepatitis (CH), 37 liver cirrhosis (LC) and 20 were healthy. Data for patient characteristics were collected, and differences between groups were analyzed by either Mann-Whitney U or χ2 tests. Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic value of AFP, G-test, and AAR for HCC.

resultsG-test, AFP, and AAR were all found to have close correlations with HCC among the different patient groups, with G-test being the most predictive for HCC among healthy and CL patients, as represented by respective areas under the curve (AUC) of 0.953 and 0.792 (P < 0.001). By contrast, AAR had the greatest diagnostic ability for HCC among CH patients (AUC = 0.850; P < 0.001). However, the combination of all 3 biomarkers obtained the most optimal results for predicting HCC onset, in terms of predictive capability for all 3 non-HCC patient groups, yielding AUCs of 0.958, 0.898, and 0.808 (P < 0.001) for, respectively, healthy, CH, and LC patients. Additionally, AFP had higher specificity, but lower sensitivity, with increased threshold values, as the recommended threshold of AFP ≥ 400 ng/mL yielded a missed diagnosis rate of 72.7%. For AFP-negative HCC (AFP-NHCC) patients, G-test alone had the greatest diagnostic capability (AUC = 0.855; P < 0.001), sensitivity (83.8%), and specificity (87.5%).

conclusionG-test has the greatest diagnostic capability for HCC and AFP-NHCC, with high sensitivity and specificity, among healthy and LC patients. However, AAR had the highest diagnostic capability and sensitivity for HCC in CH. Overall, though, the combination of G-test, AFP and AAR provided the most optimal outcomes for predicting HCC onset, no matter the patient pre-conditions.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAlanine Transaminasealpha-FetoproteinsAspartate AminotransferasesBiomarkersBiomarkers, TumorHumansLiver CirrhosisOligosaccharidesROC CurveAlanine Transaminasealpha-FetoproteinsAspartate AminotransferasesBiomarkersBiomarkers, TumorOligosaccharidesAlpha-fetoproteinAspartate aminotransferase to alanine aminotransferase ratioChronic hepatitisG-testHepatocellular carcinomaLiver cirrhosisReceiver operating characteristic curveSerological markers

Identifiers

PMID36241994
PMCPMC9563102
OpenAlexW4306160359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.